Bio

Dr. Aguiar joined Aisling in 2016 and serves as a Partner. Prior to Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million healthcare-focused venture capital and growth equity fund, from 2007 to 2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a healthcare venture capital fund, from 2001 to 2007. He was CEO of Genovo, Inc., a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997. Dr. Aguiar currently serves as a director of BridgeBio Pharma, Invitae, Biomea Fusion and Garuda Therapeutics, and as a board observer of PellePharm. His prior board service includes Amarin, CardioKine, Biohaven (acquired by Pfizer), Eidos (merged with BridgeBio), Metaphore (merged with ActivBiotics), Oriel Therapeutics (acquired by Novartis), SkinMedica, Virdante Pharmaceuticals (acquired by Momenta) and 3-D Pharmaceuticals (acquired by Johnson & Johnson). Dr. Aguiar serves as Emeritus Advisor to Tufts University School of Medicine and is a member of the Council on Foreign Relations. Dr. Aguiar received his M.D. with honors from Harvard Medical School and his B.A. with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.